SCHEMBL2650433

SCHEMBL2650433

COc1ccnc(C(C)(F)F)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.40
RXRA P19793 3/20 0.38
GRIN1 Q05586 3/20 0.38
GRIN2B Q13224 3/20 0.38
GAA P10253 1/20 0.36
LOX P28300 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
MAP4K1 Q92918 4/20 0.33
NFE2L2 Q16236 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
CCR1 P32246 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691850 1.00 NUDT1 (0.40) NUDT1RXRAGRIN1GRIN2BGAA
SCHEMBL17117534 0.86 MALT1 (0.42) NUDT1RXRAGRIN1GRIN2BGAA
SCHEMBL2625477 0.84 NUDT1 (0.42) NUDT1RXRAGRIN1GRIN2BGAA
SCHEMBL31692003 0.84 NUDT1 (0.42) NUDT1RXRAGRIN1GRIN2BGAA
SCHEMBL31691935 0.81 NUDT1 (0.41) NUDT1MAP4K1HDAC6
SCHEMBL31691836 0.81 NUDT1 (0.38) NUDT1RXRAGRIN1GRIN2BHDAC6
SCHEMBL32666802 0.78 MALT1 (0.45) NUDT1LOXLOXL2HDAC6
SCHEMBL22624172 0.75 NUDT1 (0.39) NUDT1RXRAGRIN1GRIN2BLOX
SCHEMBL30756375 0.75 ALKBH1 (0.41) NUDT1TDP1HDAC6
SCHEMBL24759681 0.74 MTNR1A (0.42) NUDT1MTNR1AMTNR1BPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383768-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-09-06 EP disclosed
US-7030128-B2 Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction MERCK SHARP & DOHME LTD. (GB) 2006-04-18 US disclosed
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-05-13 US disclosed
EP-1383768-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-28 EP disclosed
WO-2002076983-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA4 NUDT1 1109/4885RXRA 258/4885GRIN1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.